162002 20260217205446.0 doi 10.1016/j.jhin.2024.05.020 sideral 144590 ART-2024-144590 eng Gómez Zorrilla, S. Risk factors and clinical impact of multi drug resistance in healthcare-associated bacteremic urinary tract infections: a post-hoc analysis of a multi center prospective cohort in Spain 2024 Access copy available to the general public Unrestricted Background: The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48–72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11–4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37–25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25–4.69), cephalosporins (2.14; 1.35–3.41), and imipenem or meropenem (2.08; 1.03–4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay. info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00002 info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00084 info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00099 info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0004 info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0005 info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0007 info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0010 info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0011 info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0015 info:eu-repo/semantics/openAccess by-nd https://creativecommons.org/licenses/by-nd/4.0/deed.es 3.1 2024 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 99 / 421 = 0.235 2024 Q1 T1 INFECTIOUS DISEASES 45 / 137 = 0.328 2024 Q2 T1 1.017 2024 Infectious Diseases 2024 Q1 Microbiology (medical) 2024 Q1 Medicine (miscellaneous) 2024 Q1 7.5 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Becerra Aparicio, F. Sendra, E. Zamorano, L. Grau, I. Pintado, V. Padilla, B. Benito, N. Boix Palop, L Fariñas, M.C. Peñaranda, M. Gamallo, M.R. Martínez, J.A. Morte Romea, E. Universidad de Zaragoza (orcid)0000-0001-9262-2461 Del Pozo, J.L. López Montesinos, I. Durán Jordá, X. Ponz, R. Cotarelo, M. Cantón, R. Oliver, A. Ruiz Garbajosa, P. Horcajada, J.P. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 151 (2024), 173-185 J. hosp. infect. JOURNAL OF HOSPITAL INFECTION 0195-6701 362696 http://zaguan.unizar.es/record/162002/files/texto_completo.pdf Versión publicada 2590225 http://zaguan.unizar.es/record/162002/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:162002 articulos driver 2026-02-17-20:17:53 ARTICLE